• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

类固醇激素在类风湿性关节炎中的作用研究进展

王晨, 黄鑫, 江振洲, 张陆勇

王晨, 黄鑫, 江振洲, 张陆勇. 类固醇激素在类风湿性关节炎中的作用研究进展[J]. 中国药科大学学报, 2015, 46(6): 757-763. DOI: 10.11665/j.issn.1000-5048.20150621
引用本文: 王晨, 黄鑫, 江振洲, 张陆勇. 类固醇激素在类风湿性关节炎中的作用研究进展[J]. 中国药科大学学报, 2015, 46(6): 757-763. DOI: 10.11665/j.issn.1000-5048.20150621
WANG Chen, HUANG Xin, JIANG Zhenzhou, ZHANG Luyong. Advances in the role of steroids in rheumatoid arthritis[J]. Journal of China Pharmaceutical University, 2015, 46(6): 757-763. DOI: 10.11665/j.issn.1000-5048.20150621
Citation: WANG Chen, HUANG Xin, JIANG Zhenzhou, ZHANG Luyong. Advances in the role of steroids in rheumatoid arthritis[J]. Journal of China Pharmaceutical University, 2015, 46(6): 757-763. DOI: 10.11665/j.issn.1000-5048.20150621

类固醇激素在类风湿性关节炎中的作用研究进展

基金项目: 国家自然科学基金资助项目(No.81303301)

Advances in the role of steroids in rheumatoid arthritis

  • 摘要: 糖皮质激素和性激素是参与类风湿性关节炎(rheumatoid arthritis,RA)疾病治疗的主要类固醇激素,发挥着强效快速的治疗作用。本文介绍了糖皮质激素和性激素与炎症因子,免疫反应,核受体之间的关系及治疗RA的安全有效性,阐明两者治疗RA可能的作用机制,综述了类固醇激素与RA的潜在联系,为更好地使用类固醇激素治疗RA及开发治疗RA的新药提供理论参考。
    Abstract: Steroids have been used to treat rheumatoid arthritis(RA), especially glucocorticoids and sex hormones, exhibit powerful and rapid therapeutic effects. The relationship between the steroids and inflammatory cytokine, immune response, nuclear receptors, as well as the safety and efficacy of RA treatment, were introduced in this review. Meanwhile, the possible mechanism of glucocorticoids and sex hormones therapy were discussed. The potential relevance of steroids to RA was also discussed to better use steroids in the treatment of RA and to provide references for future research.
  • [1] David LS,Frederick W,Tom WJ.Rheumatoid arthritis[J].Lancet,2010,376(6):1094-1108.
    [2] Marije IK, Wim BV. Novel therapeutic targets in rheumatoid arthritis[J].Trends Pharmacol Sci,2015,36(4):1-7.
    [3] Choy EH,Isenberg DA,Costenbader KH,et al.Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis:a randomized,double-blind,placebo-controlled,dose-escalation trial[J].Arthritis Rheum,2002,46(3):3143-3150.
    [4] Karen EC,Agnes EC,Zhang ZG,et al.Changing glucocorticoid action:11β-hydroxysteroid dehydrogenase type1 in acute and chronic inflammation[J].J Steroid Biochem Mol Biol,2013,137(2):82-92.
    [5] Brewer JA, Khor B, Beastall GH, et al. T-cell glucocorticoid receptor is required to suppress COX-2-mediated lethal immune activation[J].Nat Med,2003,9(5):1318-1322.
    [6] Bhattacharyya S,Brown DE,Spector TD,et al.Macrophage glucocorticoid receptors regulate Toll-like receptor-4-mediated inflammatory responses by selective inhibition of p38 MAP kinase[J].Blood,2007,109(2):4313-4319.
    [7] Engdahl C,Jochems C,Alarcon GS,et al.Amelioration of collagen-induced arthritis and immune associated bone loss through signaling via estrogen receptor alpha,and not estrogen receptor beta or G protein-coupled receptor 30[J].Arthritis Rheum,2010,62(17):524-533.
    [8] Mueck AO,Seeger H.2-Methoxyestradiol-biology and mechanism of action[J].Steroids,2010,75(10):625-631.
    [9] Campo GM,Avenoso A,Campo S,et al.Chondroitin-4-sulphate inhibits NF-κB translocation and caspase activation in collagen-induced arthritis in mice[J].Osteoarthritis Cartilage,2008,16(12):1474-1483.
    [10] Antero S,Jari H,Johanna O,et al.Activation of innate immunity system during aging:NF-κB signaling is the molecular culprit of inflamm-aging[J].Ageing Res Rev,2008,7(2):83-105.
    [11] Jan X,Guang SF,Sha WC,et al.Methylprednisolone inhibition of TNF-α expression and NF-κB activation after spinal cord injury in rats[J].Mol Brain Res,1998,59(2):135-142.
    [12] Turnbull AV,Rivier CL.Regulation of the hypothalamic-pituitary-adrenalaxis by cytokines:actions and mechanisms of action[J].Physiol Rev,1999,79(5):1-71.
    [13] Funder JW.Mineralocorticoid receptor activation and oxidative stress[J].Hypertension,2007,50(2):840-841.
    [14] Usher MG,Duan SZ,Brown S,et al.Myeloid mineralocorticoid receptor controlsmacrophage polarization and cardiovascular hypertrophy and remodeling inmice[J].J Clin Invest,2010,120(2):3350-3364.
    [15] Frieler RA,Meng H,Hafstrom I,et al.Myeloid-specific deletion of the mineralocorticoid receptorreduces infarct volume and alters inflammation during cerebral ischemia[J].Stroke,2011,42(4):179-185.
    [16] Lim HY,Muller N,Ferlisi EM,et al.Glucocorticoids exert opposing effects on macrophage function dependent on their concentration[J].Immunology,2007,122(13):47-53.
    [17] McColl A,Michlewska S,Mirone L,et al.Effects of glucocorticoidson apoptosis and clearance of apoptotic cells[J].Sci World J,2007,7(6):1165-1181.
    [18] Agnes E, Coutinho, Karen E, et al. The anti-inflammatory and immunosuppressive effects of glucocorticoids,recent developments and mechanistic insights[J].Mol Cell Endocrinol,2011,335(1):2-13.
    [19] Bassem HD,Selma FW,Donald BD.TNF-α and glucocorticoid receptor interaction in L6 muscle cells:a cooperative downregulation of myosin heavy chain[J].Steroids,2007,72(9/10):705-712.
    [20] Etuk IA,Kaphalia L,Ferlisi EM,et al.The effect of TNF-alpha on glucocorticoid receptor translocation[J].J Allergy Clin Immun,2012,2(129):194-200.
    [21] Lin LH,Nian LY.Glucocorticoid-induced leucine zipper(GILZ)antagonizes tumor necrosis factor-alpha(TNF-α)inhibition of mesenchymal stem cell osteogenic differentiation[J].Bone,2010,47(5):417-423.
    [22] Elena AB,Jose MB,Esteban RR,et al.Glucocorticoids in rheumatoid arthritis:almost always or hardly ever[J].Reumatol Clin,2011,7(6):407-411.
    [23] Smolen JS,Landewe R,Carlstrom K,et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs[J].Ann Rheum Dis,2010,69(6):964-975.
    [24] Braun J,Baraliakos X.2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis[J].Ann Rheum Dis,2011,70(6):896-904.
    [25] Zhang W,Doherty M,Ibrahim HM,et al.EULAR recommendations for calcium pyrophosphate deposition.Part II:management[J].Ann Rheum Dis,2011,70(4):571-575.
    [26] Kirwan JR.The effect of glucocorticoids on joint destruction in rheumatoid arthritis[J].N Engl J Med,1995,333(3):142-146.
    [27] Graudal N,Jürgens G.Similar effects of disease-modifying anti-rheumatic drugs,glucocorticoids,and biological agents on radiographic progression in rheumatoid arthritis[J].Arthritis Rheum,2010,62(1):2852-2856.
    [28] Buttgereit F,Burmester GR,Lipworth BJ.Optimised glucocorticoid therapy:the sharpening of an old spear[J].Lancet,2005,365(26):801-803.
    [29] Cato AC,Schacke H,Sterry W,Asadullah K.The glucocorticoid receptor as target for classic and novel anti-inflammatory therapy[J].Curr Drug Targets Inflamm Allergy,2004,3(12):347-353.
    [30] Schacke H,Docke WD,Asadullah K.Mechanisms involved in the side effects of glucocorticoids[J].Pharmacol Ther,2002,96(11):23-43.
    [31] Cong ZD, Yao Y, Xue BF, et al. Clinical analysis of Chinese patients with rheumatoid arthritis treated with leflunomide and methotrexate combined with different dosages of glucocorticoid[J].Curr Ther Res,2012,73(4/5):123-133.
    [32] Straub RH,Dhabhar FS,Bijlsma JW,et al.How psychological stress via hormones and nerve fibers may exacerbate rheumatoid arthritis[J].Arthritis Rheum,2005,52(1):16-26.
    [33] Buttgereit F, Burmester GR, Straub RH, et al. Exogenous and endogenous glucocorticoids in rheumatic diseases[J].Arthritis Rheum,2011,63(1):1-9.
    [34] Morgan SA,Tomlinson JW.11beta-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes[J].Expert Opin Inv Drug,2010,19(9):1067-1076.
    [35] Wang M.Inhibitors of 11beta-Hydroxysteroid dehydrogenase type 1 in antidiabetic therapy[J].Handb Exp Pharmacol,2011,17(5):127-146.
    [36] Haas CS,Creighton CJ,Pi X,et al.Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins[J].Arthritis Rheum,2006,54(7):2047-2060.
    [37] Cornelia MS,Cindy S,Perry LA,et al.Glucocorticoid[J].Best Pract Res Clin Rheumatol,2011,25(6):891-900.
    [38] Hoes JN,Jacobs JW,Verstappen SM,et al.Adverse events of low-to medium-dose oral glucocorticoids in inflammatory diseases:a meta-analysis[J].Ann Rheum Dis,2009,68(12):1833-1838.
    [39] Ravindran V,Rachapalli S,Choy EH.Safety of medium to long term glucocorticoid therapy in rheumatoid arthritis:a meta-analysis[J].Rheumatology,2009,48(1):807-811.
    [40] Caporali R,Cimmino MA,Montecucco C,et al.Glucocorticoid treatment of polymyalgia rheumatica[J].Clin Exp Rheumatol,2011,29(5):S143-S147.
    [41] Silva JAP,Jacobs JWG,Kirwan JR,et al.Safety of low dose glucocorticoid treatment in rheumatoid arthritis:published evidence and prospective trial data[J].Ann Rheum Dis,2006,65(5):285-293.
    [42] Emmanuelle D,Adeline RW,Gossec L,et al.Use of glucocorticoids in rheumatoid arthritis-Pratical modalities of glucocorticoid therapy:recommendations for clinical practice based on data from the literature and expert opinion[J].Joint Bone Spine,2010,77(5):451-457.
    [43] Gorter SL,Bijlsma JW,Cutolo M,et al.Current evidence for the management of rheumatoid arthritis with glucocorticoids:a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis[J].Ann Rheum Dis,2010,69(5):1010-1014.
    [44] Sara KT,Bonnie B,Karen HC.Sexual disparities in the incidence and course of SLE and RA[J].Clin Immunol,2013,149(2):211-218.
    [45] Mohamad MN, Abeer ME. Sexual performance in rheumatoid arthritis patients—An unnoticed problem[J].The Egyptian Rheumatologist,2013,35(4):201-205.
    [46] Posma E,Moes H,Heineman MJ,et al.The effect of testosterone on cytokine production in the specific and non-specific immuneresponse[J].Am J Reprod Immunol,2004,52(2):237-243.
    [47] Delia AG,Buenaventura BD.Sex hormones and autoimmunity[J].Immunol Lett,2010,133(5):6-13.
    [48] Calippe B, Douin EV, Laffargue M, et al. Chronic estradiol administration in vivo promotes the proinflammatory response of macrophages to TLR4 activation:involvement of the phosphatidylinositol 3-kinase pathway[J].J Immunol,2008,180(4):7980-7988.
    [49] Lelu K,Laffont S.Estrogen receptor alpha signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protection against experimental autoimmune encephalomyelitis[J].J Immunol,2011,187(3):2386-2393.
    [50] Mehtap P,Akif HK.Effects of 17β-estradiol and progesterone on the production of adipokines in differentiating 3T3-L1 adipocytes:role of Rho-kinase[J].Cytokine,2015,72(1):130-134.
    [51] Takashi N,Yuuki I,Takahiro M,et al.Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts[J].Cell,2007,130(5):811-823.
    [52] Kazuki I, Erina I, Yuuki I. Female sex hormones ameliorate arthritis in SKG mice[J].Biochem Biophys Res Commun,2013,434(4):740-745.
    [53] Nathalie CB,Axelle P,Philippe B.The immninent dawn of SPRMs in obstetrics and gynecology[J].Mol Cell Endocrinol,2012,358(2):232-243.
    [54] Abarca RE,Pacheco YJ,Campos RR,et al.Glucocorticoids and estrogens modulate the NF-κB pathway differently in the micro-and macrovasculature[J].Med Hypotheses,2013,81(6):1078-1082.
计量
  • 文章访问数:  1180
  • HTML全文浏览量:  0
  • PDF下载量:  2694
  • 被引次数: 0
出版历程
  • 刊出日期:  2015-12-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭